Becton Dickinson (BDX)Officer sold ~$125K

~$125K

Approx. value · 600 sh @ $209.00

13K

Holds after · shares reported

Traded

Jan 15, 2026

Filed

Jan 16, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 9, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On October 15, 2025, the Company filed a Current Report on Form 8-K that reported that Vitor Roque, who previously served as the Company’s Senior Vice President of Finance, Business Units and Corporate Financial Planning & Analysis, was appointed as the Company’s interim Chief Financial Officer, effective December 5, 2025.”
2. Nov 17, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 17, 2025, Robert L. Huffines and Jacqueline Wright were elected to the Board of Directors (the “Board”) of Becton, Dickinson and Company (“BD”), effective December 1, 2025.”
3. Nov 17, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS. In connection with their appointments to the Board, effective December 1, 2025, Mr. Huffines and Ms. Wright will each receive restricted stock units valued at $33,575, representing a prorated grant from the effective date of their election to the Board through BD’s 2026 Annual Meeting of Shareholders.”
4. Dec 1, 2025InsiderOfficer sold ~$15K of BDX shares in the open market
5. Dec 17, 2025InsiderOfficer sold ~$123K of BDX shares in the open market
6. Dec 26, 2025InsiderOfficer sold ~$15K of BDX shares in the open market
7. Dec 30, 2025Company filing · Form 8-K · Temporary Suspension of Trading Under Registrant's Employee Benefit PlansSuspended trading under its employee plans
8. Jan 15, 2026 · this disclosureInsiderOfficer sold ~$125K of BDX shares in the open market

What came next

1. Jan 15, 2026InsiderOfficer sold ~$209K of BDX shares in the open market
2. Jan 26, 2026InsiderOfficer sold ~$15K of BDX shares in the open market
3. Jan 27, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On January 27, 2026, the Board of Directors of Becton, Dickinson and Company (“BD”) approved and adopted the BD Executive Severance Plan (the “Severance Plan”), effective January 27, 2026.”
4. Jan 30, 2026Company filing · Form 8-K · Unregistered shares, Bylaws or charterSold new shares without registering them, and changed its bylaws, charter or fiscal year
5. Jan 30, 20265% stakeThe Vanguard Group reported a passive stake (13G) of 12.8%
6. Feb 9, 2026Company filing · Form 8-K · ResultsReported its results
7. Feb 9, 2026Company filing · Form 8-K · Material agreement, Executive changeChanged a top executive or board member, and signed an important agreement (and 2 more items)“In connection with the completion of the Transactions, and effective as of the Closing, Claire M. Fraser, Ph.D., resigned as a director of the Company and was appointed to the Waters board of directors.”
8. Feb 18, 2026InsiderDirector sold ~$174K of BDX shares in the open market
9. Feb 26, 2026InsiderOfficer sold ~$14K of BDX shares in the open market
10. Mar 17, 2026CongressDisclosed sale of BDX — reported range $15,001 - $50,000
11. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
12. Mar 26, 2026InsiderOfficer sold ~$12K of BDX shares in the open market
13. Apr 2, 2026Company filing · Form 8-K · ResultsReported its results
14. Apr 6, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On April 6, 2026, Richard E. Byrd, Executive Vice President and President of the Interventional segment of Becton, Dickinson and Company (“BD”), informed BD of his intention to retire.”
15. Apr 27, 2026FDARecall: BD¿Spinal Tray with BD¿Whitacre Needle 22 G x 3.5 in.; lidocaine HCL (1%), 5 mL, bupivacaine HCL (0.75%) with dextrose (8.25%), 2 mL (marcaine). Catalog Number…
16. Apr 27, 2026FDARecall: BD¿Spinal Tray with BD¿Quincke Needle 26 G x 3.5 in.; lidocaine HCL (1%), 5 mL, bupivacaine HCL (0.75%) with dextrose (8.25%), 2 mL (marcaine). Catalog Number:…
17. Apr 27, 2026FDARecall: BD¿Spinal Tray with BD¿Whitacre Needle 25 G x 3.5 in.; lidocaine HCL (1%), 5 mL, bupivacaine HCL (0.75%) with dextrose (8.25%), 2 mL (marcaine). Catalog Number…
18. Apr 27, 2026FDARecall: BD¿Spinal Tray with BD¿Whitacre Needle 25 G x 3.5 in.; lidocaine HCL (1%), 5 mL, bupivacaine HCL (0.75%) with dextrose (8.25%), 2 mL (marcaine). Catalog Number…
19. Apr 27, 2026FDARecall: BD¿Spinal Tray with BD¿Quincke Needle 25 G x 3.5 in.; lidocaine HCL (1%), 5 mL, bupivacaine HCL (0.75%) with dextrose (8.25%), 2 mL (marcaine). Catalog Numbers…
20. Apr 27, 2026FDARecall: BD¿Spinal Tray with BD¿Whitacre Needle 25 G x 3.5 in., BD¿Quincke Needle 22 G x 3.5 in.; lidocaine HCL (1%), 5 mL, bupivacaine HCL (0.75%) with dextrose (8.25%…

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Becton Dickinson

For Becton Dickinson, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 28 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BDX page.

Other recent filings by Michael David Garrison, EVP & Pres Med.Essntl&BioPharm

• SEC Form 4 at Becton Dickinson (BDX)Jun 25, 2026
• SEC Form 4 at Becton Dickinson (BDX)Jun 11, 2026
• SEC Form 4 at Becton Dickinson (BDX)Jan 16, 2026
• SEC Form 4 at Becton Dickinson (BDX)Dec 18, 2025
• SEC Form 4 at Becton Dickinson (BDX)Jul 22, 2025

The full history of Michael David Garrison, EVP & Pres Med.Essntl&BioPharm is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Becton Dickinson

• SEC Form 4Sep 30, 2026
• SEC Form 144Sep 28, 2026
• SEC Form 4Aug 27, 2026
• SEC Form 13F-HRAug 18, 2026
• SEC Form 4Aug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its BDX page.